Table II.
Non dose-limiting toxicities possibly, probably, or definitely related to satraplatin (maximum toxicity grade per patient) observed in all patients
| Toxicity | N in cycle 1* | N in later cycles* | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Dose level 1 | Dose level 2 | All dose levels | |||||||
| Grade | Grade | Grade | |||||||
| 1 | 2 | 3 | 1 | 2 | 3 | 1 | 2 | 3 | |
| Hematologic | |||||||||
| Anemia | 2 | 1 | 3 | 1 | 1 | 1 | 1 | ||
| Lymphopenia | 1 | 2 | 1 | 1 | 1 | 1 | 2 | 3 | |
| Neutropenia | 1 | 2 | 1 | 1 | 2 | 3 | |||
| Thrombocytopenia | 2 | 1 | 1 | 1 | 1 | 1 | 3 | 2 | 1 |
| Cardiac | |||||||||
| Palpitations | 1 | ||||||||
| Constitutional | |||||||||
| Fatigue | 1 | 2 | 2 | 2 | |||||
| Generalized muscle weakness | 1 | ||||||||
| Myalgia | 1 | ||||||||
| Pain | 2 | 2 | |||||||
| Gastrointestinal | |||||||||
| Abdominal pain | 1 | 1 | 1 | ||||||
| Constipation | 1 | 1 | 1 | ||||||
| Diarrhea | 1 | 1 | 1 | 1 | |||||
| Nausea | 2 | 1 | 1 | 1 | 4 | ||||
| Vomiting | 1 | 1 | 1 | 2 | |||||
| Oral mucositis | 1 | 1 | |||||||
| Gum bleeding | 1 | ||||||||
| Metabolism/laboratory | |||||||||
| Anorexia | 2 | 3 | 1 | 1 | |||||
| Dehydration | 1 | ||||||||
| Weight loss | 1 | ||||||||
| Hypercalcemia | 1 | 2 | |||||||
| Hyperkalemia | 1 | ||||||||
| Hypermagnesemia | 1 | 1 | |||||||
| Hypernatremia | 1 | 1 | |||||||
| Hypoalbuminemia | 1 | ||||||||
| Hypokalemia | 1 | 1 | 2 | ||||||
| Hypomagnesemia | 1 | 1 | 2 | ||||||
| Hyponatremia | 1 | ||||||||
| Increased ALT | 2 | 1 | |||||||
| Increased AST | 1 | 1 | |||||||
| Increased alkaline phosphatase | 1 | 2 | 1 | 2 | |||||
| Increased bilirubin | 1 | ||||||||
| Neurologic/Psychiatric | |||||||||
| Dizziness | 1 | 1 | |||||||
| Headache | 2 | 1 | 2 | ||||||
| Anxiety | 1 | ||||||||
| Renal | |||||||||
| Proteinurea | 1 | 1 | |||||||
| Respiratory | |||||||||
| Dyspnea | 1 | ||||||||
| Dermatologic | |||||||||
| Rash | 1 | 1 | 1 | ||||||
| Bruising | 1 | ||||||||
| Hearing impairment | 1 | ||||||||
*
N=number of patients